Urothelial Cancer Drugs Market Report 2025

The urothelial cancer drugs market size has grown exponentially in recent years. It will grow from $2.81 billion in 2024 to $3.4 billion in 2025 at a compound annual growth rate (CAGR) of 21.1%. The growth in the historic period can be attributed to awareness and early detection initiatives, physician education and training, patient advocacy groups, evolving standard of care, biomarker identification.

The urothelial cancer drugs market size is expected to see rapid growth in the next few years. It will grow to $7.04 billion in 2029 at a compound annual growth rate (CAGR) of 20%. The growth in the forecast period can be attributed to advancements in diagnostic imaging, artificial intelligence in drug development, patient-centric care, investment in research & development, regulatory changes. Major trends in the forecast period include advances in imaging technologies, patient-centric care, healthcare reimbursement, genomic profiling, regulatory frameworks.

The increasing prevalence of urothelial cancer is anticipated to boost the urothelial cancer drug market in the future. Urothelial cancer involves the urothelial cells that line various organs, including the urethra, bladder, ureters, and renal pelvis. The growing incidence of urothelial cancer necessitates the development of new drugs and therapies to treat this condition and reduce mortality rates. For example, in January 2023, the American Cancer Society Inc., a US-based voluntary health organization, reported that approximately 62,420 men and 19,870 women were diagnosed with bladder cancer, out of a total of 82,290 new cases. Additionally, there were 16,710 deaths attributed to bladder cancer, comprising 4,550 women and 12,160 men. Therefore, the rising prevalence of urothelial cancer is expected to drive the growth of the urothelial cancer drug market.

The increasing demand for chemotherapy is set to propel the growth of the urothelial cancer drugs market. Chemotherapy, a systemic treatment circulating throughout the body via the bloodstream, proves effective against cancer cells that may have spread to distant sites. Its application in urothelial cancer management includes inhibiting cancer cell growth, treating metastatic disease, targeting rapidly dividing cells, and providing palliative care to relieve symptoms and improve patients' quality of life. As reported in February 2022 by Healthcare IT News, the demand for cancer chemotherapy is expected to rise from 10 million to 15 million by 2040, according to the Union for International Cancer Control (UICC). The increasing demand for chemotherapy underscores its crucial role in urothelial cancer treatment, contributing to the growth of the urothelial cancer drugs market.

The rising prevalence of the geriatric population is contributing to the growth of the urothelial cancer drugs market. Individuals aged 65 and older are classified as part of the geriatric population. Due to weakened immunity and advanced age, older adults are more vulnerable to various diseases. The risk of urothelial cancer increases with age, which creates a demand for urothelial cancer drugs to treat this population. For example, in October 2022, the World Health Organization, a US-based specialized health agency, projected that globally, 1 in 6 people will be 60 or older by 2030, with the number of individuals in this age group expected to double to 2.1 billion by 2050. Furthermore, according to data published by the Population Reference Bureau, a US-based nonprofit organization, the population of Americans aged 65 and older is expected to grow from 58 million in 2022 to 82 million by 2050, representing a 47% increase, with this age group’s share of the total population rising from 17% to 23%. Therefore, the increasing prevalence of the geriatric population is set to drive the urothelial cancer drugs market.

Novel combination therapies are emerging as a significant trend in the urothelial cancer drug market. Combination therapy involves the use of two or more therapeutic agents for treatment. Key players are focusing on developing combination therapies to maintain their position in the urothelial cancer drug market. The integration of immunotherapy with targeted drugs offers a promising approach to mitigate the development of resistance and enhance response in cancer management. For example, in July 2022, the United States Food and Drug Administration (FDA), a federal agency within the Department of Health and Human Services, approved the biologics license application (BLA) for ImmunityBio’s N-803, an IL-15 superagonist, in combination with the Bacillus Calmette-Guerin (BCG) vaccine for bladder cancer. This marks the first immunotherapy combination that can be administered directly to stimulate natural killer cells and T cells within the bladder.

Prominent companies in the urothelial cancer drugs market are prioritizing product approvals, such as Padcev in combination with Keytruda, to enhance revenues in the market. The Padcev-Keytruda combination represents a therapeutic option for treating urothelial cancer. For instance, in April 2023, Astellas Pharma Inc., a Japan-based pharmaceutical company, received FDA approval for Padcev with Keytruda. This combination therapy is indicated for metastatic urothelial cancer. When cisplatin-containing chemotherapy is unsuitable for certain patients with locally advanced or metastatic urothelial carcinoma, the Padcev and pembrolizumab combination is recommended as the initial line of treatment. In patients with advanced bladder cancer, the Padcev-Keytruda combination has shown a significant improvement in overall survival and progression-free survival rates.

Major companies operating in the urothelial cancer drugs market are F Hoffmann La Roche AG, The Bristol-Myers Squibb Company, Merck & Co Inc., Pfizer Inc., Genentech Inc., GSK PLC, UroGen Pharma Inc., Johnson & Johnson Inc., Astellas Pharma Inc., Sesen Bio Inc., Seagen Inc., Eisai Co. Ltd., Agensys Inc., AstraZeneca, Novartis AG, GlaxoSmithKline PLC, Sanofi SA, Janssen Pharmaceuticals Inc., Seattle Genetics Inc., AbbVie Inc., Millennium Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Spectrum Pharmaceuticals Inc., Zydus Lifesciences Ltd.

North America was the largest region in the urothelial cancer drugs market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the urothelial cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the urothelial cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Urothelial cancer drugs encompass medications and therapies designed to target and treat cancer associated with urothelial cells lining the urethra, bladder, ureters, and renal pelvis. These treatments aim to eliminate cancerous cells and offer non-vesical chemotherapy options. They are primarily utilized for both prevention and treatment of urothelial cancer.

The main types of urothelial cancer include urothelial carcinoma, squamous cell carcinoma, and adenocarcinoma. Urothelial carcinoma specifically addresses epithelial tissue tumors, referring to transitional cell cancer occurring near epithelial tissues. Urothelial cancer drugs typically encompass treatment approaches such as immunotherapy, chemotherapy, and preservation therapy, all tailored for managing urothelial cancer. These drugs are distributed through various channels including hospital pharmacies, specialty clinics, cancer institutes, and ambulatory surgical centers.

The urothelial cancer drugs market research report is one of a series of new reports that provides urothelial cancer drugs market statistics, including urothelial cancer drugs industry global market size, regional shares, competitors with a urothelial cancer drugs market share, detailed urothelial cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the urothelial cancer drugs industry. This urothelial cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The urothelial cancer drugs market consists of sales of targeted therapy urothelial cancer drugs and chemo therapy urothelial cancer drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.